At present the safety of p75NTR inhibition with LM11A-31 is being investigated in a phase 2 trial (ClinicalTrials.gov Identifier: NCT03069014) to test its use in the treatment of Alzheimer’s disease patients. The gene discussed is NGFR; the disease is early-onset autosomal dominant Alzheimer disease.